In addition, DLBCL-activated FRCs (DLBCL-FRCs) inhibited CD8+ TIL cytolytic activity via aberrant expression of PD-1 ligands (PD-L1 and PD-L2). This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.